IGC Pharma, Inc. (IGC) - Q1 2026 (Ended June 30, 2025) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025 (Q1 of Fiscal 2026). IGC Pharma is a clinical-stage pharmaceutical company focused on developing treatments for Alzheimer's disease (AD) and related neurodegenerative conditions. The company's lead investigational candidate, IGC-AD1, is in Phase 2 clinical trials targeting agitation in Alzheimer's patients. The company also operates a Life Sciences segment generating revenue through white-label manufacturing and wellness products.
Key Financial Metrics
| Metric | Q1 2026 (Three Months Ended June 30, 2025) | Q1 2025 (Three Months Ended June 30, 2024) |
|---|---|---|
| Revenue | $328,000 | $272,000 |
| Gross Profit | $154,000 | $163,000 |
| Gross Margin | 47% | 60% |
| Operating Loss | $(1,905,000) | $(2,396,000) |
| Net Loss | $(1,599,000) | $(2,378,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.02) | $(0.03) |
| Cash and Cash Equivalents (End of Period) | $454,000 | $1,824,000 |
| Working Capital | $428,000 | $639,000 (Prior Year End) |
| Long-Term Debt | $133,000 (EIDL Loan) | $134,000 |
| Available Credit Facility | $12,000,000 (Unutilized) | $12,000,000 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 21% ($56,000) year-over-year, driven primarily by white-label services ($322,000 vs. $251,000).
- Reduced Losses: Net loss decreased by 33% ($779,000 improvement) compared to the prior year quarter. Operating loss improved by 20%.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased by 28% ($462,000) due to headcount alignment and reduced legal/professional fees. R&D expenses decreased by 4% ($38,000), excluding a one-time non-cash expense in the prior year.
- Other Income: Other income surged 1,600% to $306,000, primarily due to a $263,000 tax credit and a $24,000 profit from the sale of an asset held for sale (Nagpur land).
- Cash Position: Cash and cash equivalents declined significantly from the prior year-end ($1.82M) to $454,000, though they increased slightly ($49,000) from the previous quarter.
Guidance, Outlook, and Risks
- Clinical Progress: Management highlighted promising early results from the Phase 2 trial of IGC-AD1, noting a potentially faster onset of action (within two weeks) compared to traditional medications. The company is expanding clinical trial sites across North America.
- AI Development: The company is developing "MINT-AD," an AI-driven diagnostic platform for early Alzheimer's detection, aiming to bridge the gap in primary care diagnostics.
- Liquidity Strategy: The company extended its $12 million credit facility with O-Bank on June 24, 2025, reducing facility fees from $84,000 to $48,000 but increasing the interest margin to 1.2%. Management believes current cash and the credit facility are sufficient for at least 12 months.
- Capital Raising: The company raised approximately $997,000 in the quarter via private placements and At-The-Market (ATM) offerings. Subsequent to quarter-end (through July 31, 2025), an additional $2.62 million was raised via ATM.
- Digital Asset Risk: Management announced a plan to invest a portion of cash reserves in digital assets (e.g., Bitcoin) starting in the quarter ending September 30, 2025. This introduces significant volatility and regulatory risks to the balance sheet.
- Legal Proceedings: A material contractual dispute remains pending in Colombia involving charges of fraud and falsification of documents; no material changes occurred during the quarter.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $454,000 cash balance against the $1.4 million quarterly operating cash burn rate.
- Credit Facility Terms: Confirm the specific interest rate calculation (Certificate of Deposit rate + 1.2%) and any covenants attached to the $12 million O-Bank facility.
- Digital Asset Policy: Review the specific treasury policy details regarding the proposed investment in cryptocurrencies and the associated risk management framework.
- Clinical Trial Milestones: Monitor the timeline and enrollment status of the IGC-AD1 Phase 2 trial (CALMA trial) and the development progress of the MINT-AD AI platform.
- Revenue Sustainability: Assess the long-term viability of the white-label revenue stream as the company shifts focus and resources toward core pharmaceutical R&D.
- Legal Exposure: Track the status of the pending litigation in Colombia for potential financial impact or operational disruption.